Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 1;7(4):e244266.
doi: 10.1001/jamanetworkopen.2024.4266.

Reliability and Validity of Smartphone Cognitive Testing for Frontotemporal Lobar Degeneration

Collaborators, Affiliations

Reliability and Validity of Smartphone Cognitive Testing for Frontotemporal Lobar Degeneration

Adam M Staffaroni et al. JAMA Netw Open. .

Abstract

Importance: Frontotemporal lobar degeneration (FTLD) is relatively rare, behavioral and motor symptoms increase travel burden, and standard neuropsychological tests are not sensitive to early-stage disease. Remote smartphone-based cognitive assessments could mitigate these barriers to trial recruitment and success, but no such tools are validated for FTLD.

Objective: To evaluate the reliability and validity of smartphone-based cognitive measures for remote FTLD evaluations.

Design, setting, and participants: In this cohort study conducted from January 10, 2019, to July 31, 2023, controls and participants with FTLD performed smartphone application (app)-based executive functioning tasks and an associative memory task 3 times over 2 weeks. Observational research participants were enrolled through 18 centers of a North American FTLD research consortium (ALLFTD) and were asked to complete the tests remotely using their own smartphones. Of 1163 eligible individuals (enrolled in parent studies), 360 were enrolled in the present study; 364 refused and 439 were excluded. Participants were divided into discovery (n = 258) and validation (n = 102) cohorts. Among 329 participants with data available on disease stage, 195 were asymptomatic or had preclinical FTLD (59.3%), 66 had prodromal FTLD (20.1%), and 68 had symptomatic FTLD (20.7%) with a range of clinical syndromes.

Exposure: Participants completed standard in-clinic measures and remotely administered ALLFTD mobile app (app) smartphone tests.

Main outcomes and measures: Internal consistency, test-retest reliability, association of smartphone tests with criterion standard clinical measures, and diagnostic accuracy.

Results: In the 360 participants (mean [SD] age, 54.0 [15.4] years; 209 [58.1%] women), smartphone tests showed moderate-to-excellent reliability (intraclass correlation coefficients, 0.77-0.95). Validity was supported by association of smartphones tests with disease severity (r range, 0.38-0.59), criterion-standard neuropsychological tests (r range, 0.40-0.66), and brain volume (standardized β range, 0.34-0.50). Smartphone tests accurately differentiated individuals with dementia from controls (area under the curve [AUC], 0.93 [95% CI, 0.90-0.96]) and were more sensitive to early symptoms (AUC, 0.82 [95% CI, 0.76-0.88]) than the Montreal Cognitive Assessment (AUC, 0.68 [95% CI, 0.59-0.78]) (z of comparison, -2.49 [95% CI, -0.19 to -0.02]; P = .01). Reliability and validity findings were highly similar in the discovery and validation cohorts. Preclinical participants who carried pathogenic variants performed significantly worse than noncarrier family controls on 3 app tasks (eg, 2-back β = -0.49 [95% CI, -0.72 to -0.25]; P < .001) but not a composite of traditional neuropsychological measures (β = -0.14 [95% CI, -0.42 to 0.14]; P = .32).

Conclusions and relevance: The findings of this cohort study suggest that smartphones could offer a feasible, reliable, valid, and scalable solution for remote evaluations of FTLD and may improve early detection. Smartphone assessments should be considered as a complementary approach to traditional in-person trial designs. Future research should validate these results in diverse populations and evaluate the utility of these tests for longitudinal monitoring.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Staffaroni reported being a coinventor of 4 ALLFTD mobile application tasks (not analyzed in the present study) and receiving licensing fees from Datacubed Health; receiving research support from the National Institute on Aging (NIA) of the National Institutes of Health (NIH), Bluefield Project to Cure FTD, the Alzheimer’s Association, the Larry L. Hillblom Foundation, and the Rainwater Charitable Foundation; and consulting for Alector Inc, Eli Lilly and Company/Prevail Therapeutics, Passage Bio Inc, and Takeda Pharmaceutical Company. Dr Forsberg reported receiving research support from the NIH. Dr Rankin reported receiving research support from the NIH and the National Science Foundation and serving on the medical advisory board for Eli Lilly and Company. Dr Appleby reported receiving research support from the Centers for Disease Control and Prevention (CDC), the NIH, Ionis Pharmaceuticals Inc, Alector Inc, and the CJD Foundation and consulting for Acadia Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, and Sangamo Therapeutics Inc. Dr Bayram reported receiving research support from the NIH. Dr Domoto-Reilly reported receiving research support from NIH and serving as an investigator for a clinical trial sponsored by Lawson Health Research Institute. Dr Bozoki reported receiving research funding from the NIH, Alector Inc, Cognition Therapeutics Inc, EIP Pharma, and Transposon Therapeutics Inc; consulting for Eisai and Creative Bio-Peptides Inc; and serving on the data safety monitoring board for AviadoBio. Dr Fields reported receiving research support from the NIH. Dr Galasko reported receiving research funding from the NIH; clinical trial funding from Alector Inc and Esai; consulting for Esai, General Electric Health Care, and Fujirebio; and serving on the data safety monitoring board of Cyclo Therapeutics Inc. Dr Geschwind reported consulting for Biogen Inc and receiving research support from Roche and Takeda Pharmaceutical Company for work in dementia. Dr Ghoshal reported participating in clinical trials of antidementia drugs sponsored by Bristol Myers Squibb, Eli Lilly and Company/Avid Radiopharmaceuticals, Janssen Immunotherapy, Novartis AG, Pfizer Inc, Wyeth Pharmaceuticals, SNIFF (The Study of Nasal Insulin to Fight Forgetfulness) study, and A4 (The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease) trial; receiving research support from Tau Consortium and the Association for Frontotemporal Dementia; and receiving funding from the NIH. Dr Graff-Radford reported receiving royalties from UpToDate; reported participating in multicenter therapy studies by sponsored by Biogen Inc, TauRx Therapeutics Ltd, AbbVie Inc, Novartis AG, and Eli Lilly and Company; and receiving research support from the NIH. Dr Grossman reported receiving grant support from the NIH, Avid Radiopharmaceuticals, and Piramal Pharma Ltd; participating in clinical trials sponsored by Biogen Inc, TauRx Therapeutics Ltd, and Alector Inc; consulting for Bracco and UCB; and serving on the editorial board of Neurology. Dr Hsiung reported receiving grant support from the Canadian Institutes of Health Research, the NIH, and the Alzheimer Society of British Columbia; participating in clinical trials sponsored by Anavax Life Sciences Corp, Biogen Inc, Cassava Sciences, Eli Lilly and Company, and Roche; and consulting for Biogen Inc, Novo Nordisk A/S, and Roche. Dr Huey reported receiving research support from the NIH. Dr Jones reported receiving research support from the NIH. Dr Litvan reported receiving research support from the NIH, the Michael J Fox Foundation, the Parkinson Foundation, the Lewy Body Association, CurePSP, Roche, AbbVie Inc, H Lundbeck A/S, Novartis AG, Transposon Therapeutics Inc, and UCB; serving as a member of the scientific advisory board for the Rossy PSP Program at the University of Toronto and for Amydis; and serving as chief editor of Frontiers in Neurology. Dr Masdeu reported consulting for and receiving research funding from Eli Lilly and Company; receiving personal fees from GE Healthcare; receiving grant funding and personal fees from Eli Lilly and Company; and receiving grant funding from Acadia Pharmaceutical Inc, Avanir Pharmaceuticals Inc, Biogen Inc, Eisai, Janssen Global Services LLC, the NIH, and Novartis AG outside the submitted work. Dr Mendez reported receiving research support from the NIH. Dr Miyagawa reported receiving research support from the Zander Family Foundation. Dr Pascual reported receiving research support from the NIH. Dr Pressman reported receiving research support from the NIH. Dr Ramos reported receiving research support from the NIH. Dr Roberson reported receiving research support from the NIA of the NIH, the Bluefield Project, and the Alzheimer’s Drug Discovery Foundation; serving on a data monitoring committee for Eli Lilly and Company; receiving licensing fees from Genentech Inc; and consulting for Applied Genetic Technologies Corp. Dr Tartaglia reported serving as an investigator for clinical trials sponsored by Biogen Inc, Avanex Corp, Green Valley, Roche/Genentech Inc, Bristol Myers Squibb, Eli Lilly and Company/Avid Radiopharmaceuticals, and Janssen Global Services LLC and receiving research support from the Canadian Institutes of Health Research (CIHR). Dr Wong reported receiving research support from the NIH. Dr Kornak reported providing expert witness testimony for Teva Pharmaceuticals Industries Ltd, Apotex Inc, and Puma Biotechnology and receiving research support from the NIH. Dr Kremers reported receiving research funding from NIH. Dr Kramer reported receiving research support from the NIH and royalties from Pearson Inc. Dr Boeve reported serving as an investigator for clinical trials sponsored by Alector Inc, Biogen Inc, and Transposon Therapeutics Inc; receiving royalties from Cambridge Medicine; serving on the Scientific Advisory Board of the Tau Consortium; and receiving research support from NIH, the Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program, and the Little Family Foundation. Dr Rosen reported receiving research support from Biogen Inc, consulting for Wave Neuroscience and Ionis Pharmaceuticals, and receiving research support from the NIH. Dr Boxer reported being a coinventor of 4 of the ALLFTD mobile application tasks (not the focus of the present study) and previously receiving licensing fees; receiving research support from the NIH, the Tau Research Consortium, the Association for Frontotemporal Degeneration, Bluefield Project to Cure Frontotemporal Dementia, Corticobasal Degeneration Solutions, the Alzheimer’s Drug Discovery Foundation, and the Alzheimer’s Association; consulting for Aeovian Pharmaceuticals Inc, Applied Genetic Technologies Corp, Alector Inc, Arkuda Therapeutics, Arvinas Inc, AviadoBio, Boehringer Ingelheim, Denali Therapeutics Inc, GSK, Life Edit Therapeutics Inc, Humana Inc, Oligomerix, Oscotec Inc, Roche, Transposon Therapeutics Inc, TrueBinding Inc, and Wave Life Sciences; and receiving research support from Biogen Inc, Eisai, and Regeneron Pharmaceuticals Inc. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Screenshots of Smartphone Cognitive Tests and Testing Schedule
Screenshots of the smartphone cognitive tasks developed by Datacubed Health and included in the ALLFTD Mobile App. Details about the task design and instructions are included in the eMethods in Supplement 1. A, Flanker (Ducks in a Pond) is a task of cognitive control requiring participants to select the direction of the center duck. B, Go/no-go (Go Sushi Go!) requires participants to quickly tap on pieces of sushi (go) but not to tap when they see a fish skeleton (no-go). C, Card sort (Card Shuffle) is a task of cognitive flexibility requiring participants to learn rules that change during the task. D, The adaptative, associative memory task (Humi’s Bistro) requires participants to learn the food orders of several restaurant tables. E, Stroop (Color Clash) is a cognitive inhibition paradigm requiring participants to inhibit their tendency to read words and instead respond based on the color of the word. F, The 2-back task (Animal Parade) requires participants to determine whether animals on a parade float match the animals they saw 2 stimuli previously. G, Participants are asked to complete 3 testing sessions over 2 weeks. Shown in dark blue, they have 3 days to complete each testing session with a washout day between sessions on which no tests are available. Session 2 always begins on day 5 and session 3 on day 9. Screenshots are provided with permission from Datacubed Health.
Figure 2.
Figure 2.. Reliability of Smartphone Cognitive Tests in a Mixed Sample of Adults Without Functional Impairment and Participants With Frontotemporal Lobar Degeneration
Forest plots present internal consistency and test-retest reliability results in the discovery and validation cohorts, as well as an estimate in a combined sample of discovery and validation participants. ICC indicates interclass correlation coefficient.
Figure 3.
Figure 3.. Association of Smartphone Cognitive Tests With Criterion Standards and Detection of Deficits in Early Frontotemporal Lobar Degeneration (FTLD)
A and B, Correlation matrices display associations of in-clinic criterion standard measures and ALLFTD mobile App (mApp) test scores in discovery and validation cohorts. Below the horizontal dashed lines, the associations among app tests and between app tests and demographic characteristics convergent clinical measures, divergent cognitive tests, and neuroimaging regions of interest can be viewed. Most app tests show strong correlations with each other and with age, convergent clinical measures, and brain volume. The measures show weaker correlations with divergent measures of visuospatial (Benson Figure Copy) and language (Multilingual Naming Test [MINT]) abilities. The strength of convergent correlations between app measures and outcomes is similar to the correlations between criterion standard neuropsychological scores and these outcomes, which can be viewed by looking across the rows above the horizontal black line. C and D, In the discovery and validation cohorts, receiver operating characteristics curves were calculated to determine how well a composite of app tests, the Uniform Data Set, version 3.0, Executive Functioning Composite (UDS3-EF), and the Montreal Cognitive Assessment (MoCA) discriminate individuals without symptoms (Clinical Dementia Rating Scale plus National Alzheimer’s Coordinating Center FTLD module sum of boxes [CDR plus NACC-FTLD-SB] score = 0) from individuals with the mildest symptoms of FTLD (CDR plus NACC-FTLD-SB score = 0.5). AUC indicates area under the curve; CVLT, California Verbal Learning Test.

References

    1. Boeve BF, Boxer AL, Kumfor F, Pijnenburg Y, Rohrer JD. Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations. Lancet Neurol. 2022;21(3):258-272. doi:10.1016/S1474-4422(21)00341-0 - DOI - PubMed
    1. Malzbender K, Lavina-Mena L, Hughes L, Bose N, Goldman D, Patel D. Key barriers to clinical trials for Alzheimer’s disease. August 17, 2020. Accessed June 21, 2023. https://healthpolicy.usc.edu/research/key-barriers-for-clinical-trials-f...
    1. Apostolaros M, Babaian D, Corneli A, et al. . Legal, regulatory, and practical issues to consider when adopting decentralized clinical trials: recommendations from the Clinical Trials Transformation Initiative. Ther Innov Regul Sci. 2020;54(4):779-787. doi:10.1007/s43441-019-00006-4 - DOI - PMC - PubMed
    1. Staffaroni AM, Quintana M, Wendelberger B, et al. ; Frontotemporal Dementia Prevention Initiative (FPI) Investigators . Temporal order of clinical and biomarker changes in familial frontotemporal dementia. Nat Med. 2022;28(10):2194-2206. doi:10.1038/s41591-022-01942-9 - DOI - PMC - PubMed
    1. Papp KV, Samaroo A, Chou HC, et al. . Unsupervised mobile cognitive testing for use in preclinical Alzheimer’s disease. Alzheimers Dement (Amst). 2021;13(1):e12243. doi:10.1002/dad2.12243 - DOI - PMC - PubMed

Publication types